Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Ranolazine (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Gilead Sciences
- 28 Jan 2014 Planned number of patients changed from 420 to 400 according to European Clinical Trials Database record.
- 12 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 21 Aug 2013 Planned end date changed from 1 Mar 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.